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Abstract
Background: Myoclonus–dystonia is a condition that manifests predominantly as myoclonic jerks with focal dystonia. It is genetically heterogeneous with most
mutations in the epsilon sarcoglycan gene (SGCE). In medically refractory cases, deep brain stimulation (DBS) has been shown to provide marked sustainable clinical
improvement, especially in SGCE-positive patients. We present two patients with myoclonus–dystonia (one SGCE positive and the other SGCE negative) who have
the isolated myoclonus phenotype and had DBS leads implanted in the bilateral globus pallidus internus (GPi).
Methods: We review their longitudinal Unified Myoclonus Rating Scale scores along with their DBS programming parameters and compare them with published
cases in the literature.
Results: Both patients demonstrated complete amelioration of all aspects of myoclonus within 6–12 months after surgery. The patient with the SGCE-negative mutation
responded just as well as the patient who was SGCE positive. High-frequency stimulation (130 Hz) with amplitudes greater than 2.5 V provided therapeutic benefit.
Discussion: This case series demonstrates that high frequency GPi-DBS is effective in treating isolated myoclonus in myoclonus–dystonia, regardless of the presence of
SGCE mutation.
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Introduction
Myoclonus–dystonia (MD) is an autosomal dominant disorder that
presents with myoclonic jerks and dystonia, although pure myoclonus may
be the only manifestation.1 Myoclonic jerks are the predominant feature,
usually occurring in the upper body including the neck, shoulders, and
arms, and are dramatically responsive to alcohol.2 MD is genetically
heterogenous with most mutations or deletions in the epsilon sarcoglycan
gene (SGCE).3–5 However, approximately 50% of MD patients are SGCE
negative, although new genes and loci have been found in some
pedigrees.3,4 Oftentimes oral medications do not provide optimal symptom
benefit. Deep brain stimulation (DBS) has proven to be an efficient and
sustainable therapy for such patients, especially in those who are SGCE
positive.6–18 We report on two patients with MD—one SGCE positive, the
other SGCE negative—with isolated myoclonus phenotypes that were
refractory to medications and successfully treated with bilateral globus
pallidus internus deep brain stimulation (GPi-DBS). We show, through
reviewing longitudinal Unified Myoclonus Rating Scale (UMRS) scores,
that all aspects of myoclonus, regardless of its location on the body,
disappear. This response was realized within 6 weeks of stimulation for both
patients, despite their genetic heterogeneity. Furthermore, when combined
with published cases in the established literature, there is a suggestion that
high frequency with moderate to high voltage drives this therapeutic gain.
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Methods
Patient 1
The first patient was a 30-year-old male who had developed jerking
movements of the trunk and left arm in childhood. When he walked these
movements worsened, and they dampened with running or leaning on his
elbows. Genetic testing was positive for an SGCE gene mutation and he
responded partially to both clonazepam (1 mg three times a day) as well as
sodium oxybate (2–3 g daily), but he remained quite impaired. Alcohol (i.e.,
six shots of vodka) also provided complete symptomatic relief. Family history
was negative. On physical examination (Video 1) there were frequent
myoclonic jerks of his torso and left arm when sitting at rest. Leaning
forward attenuated the myoclonus briefly, but it would be exacerbated
when walking or doing any other activity such as writing, typing, reaching
for items, or eating. There was no myoclonus in his face, right arm, or lower
limbs. Stimulation-induced myoclonus was present with claps. He showed
no dystonic posturing at rest or with tasks such as writing. His presurgical
rest, action, and stimulus UMRS subscores were 21, 38, and 2, respectively.
Patient 2
A 16 year-old female presented with a 3-year history of myoclonic jerks,
predominantly on the right side. At the age of 13 years, she developed
Figure 1. Postoperative T2-weighted Magnetic Images of Globus Pallidus Internus (GPi) Electrode Positioning with Coordinates in Anterior
Commissure - Posterior Commissure Line Space. Patient 1: (A) coronal image of GPi electrodes; (B) axial image showing most ventral tip of electrodes
(arrows) in GPi (Left: X 5 219.1, Y 5 +2.2, Z 5 24.1; Right: X 5 19.1, Y 5 2.2, Z 5 24.4). Patient 2: (C) coronal image of GPi electrodes; (D) axial image
showing most ventral tip of electrodes (arrows) in GPi (Left: X 5 220.1, Y 5 1.5, Z 5 23.2; Right: X 5 19.3, Y 5 2.0, Z 5 23.5).
Ramdhani RA, Frucht SJ, Behnegar A, et al. DBS for Isolated Myoclonus in Myoclonus Dystonia
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services2
myoclonic jerks of her right arm and forearm that interfered with writing
and holding items. Over the subsequent years, her gait deteriorated
because of the emergence of right leg myoclonus triggered by walking.
Treatment with trihexyphenidyl (2 mg three times a day), clonazepam
(0.5 mg daily), and botulinum toxin injections provided only modest
benefit. Genetic testing was negative for SGCE mutations and brain
magnetic resonance imaging (MRI) was normal. The family history was
notable for tic disorder, which our patient also had in the past (i.e., eye
blinking tics) before the onset of her condition. On physical examination
(Video 2) while sitting at rest, there were myoclonic jerks present in her
right arm and neck. There was no myoclonus on her left side. When she
stood and walked, frequent action-induced myoclonus of the right leg
produced an unsteady gait. Stimulation-induced myoclonus was absent.
There was no dystonia in her face, neck, or limbs or when performing
tasks such as writing. Her presurgical UMRS rest and action myoclonus
subscores were 8 and 15, respectively.
Electrode implantation
Both patients underwent staged implantation of bilateral DBS electrodes
(Medtronic 3389, Minneapolis, MN/USA) into the posteroventrolateral
GPi using a Leksell stereotactic frame and O-Arm guidance. The operative
target was localized as 20 mm lateral to the midline, 2.5 mm anterior to the
middle cerebral peduncle and 4 mm inferior to the commissural
line. The target was then cross-correlated with the reformatted
Schaltenbrand and Wahren atlas and with quantitative susceptibility
mapping19 images showing the GPi. Intraoperative microelectrode
recording provided further targeting refinement and postoperative
MRI provided confirmation of electrode placement (Figure 1). The pulse
generators (Activa SC, Medtronic, Inc) were implanted in the subclavicular
region in both patients.
Postoperative programming commenced 4 weeks from placement of
the second electrode and consisted of a monopolar review (pulse width
[PW] 60 ms, frequency 130 Hz) that determined the threshold for
adverse effects such as muscle contractions and visual phosphenes.
Contact(s) that provided visible myoclonus reduction together with
unwanted side effects were chosen as the therapeutic contact(s).
Amplitude was initially set at approximately 20% below the threshold
for side effects, and incrementally increased over the subsequent weeks.
Longitudinal unblinded subscores of the UMRS (rest, action,
stimulation-induced myoclonus) were evaluated for both patients.
Table 1. Pre- and Postoperative Unified Myoclonus Rating Scale Scores
Rest Action Stimulus % Change
Patient 1
Preoperative 21 38 2
Postoperative
6 weeks 0 0 0 2100/2100/2100
7 month 2 4 0 290/289/2100
2 years 0 0 0 2100/2100/2100
3 years 0 0 0 2100/2100/2100
Patient 2
Postoperative
Preoperative 8 15 0 –
Postoperative
1 week 1 5 0 288/267
1 month 0 2 0 2100/287
2 month 0 0 0 2100/2100
3 month 0 0 0 2100/2100
4 month 0 2 0 2100/287
5 month 0 1 0 2100/293
6 month 0 2 0 2100/287
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Results
Both patients showed complete resolution of myoclonus with
stimulation within 1 year of stimulation (Table 1). Considerable
benefits were evident as early as 1 week (Patient 2), and by 4–6 weeks
both rest and action myoclonus were substantially attenuated in both
patients. Stimulus-sensitive myoclonus seen in Patient 1 disappeared.
Writing improved for both patients along with feeding, typing, and
walking. This response has been sustained in both patients, with no
evidence of myoclonic jerks over 3 years in Patient 1 (Video 1) and
6 months for Patient 2 (Video 2).
High-frequency stimulation (130 Hz) was utilized in both patients.
Dorsally located contact 2 was associated with robust myoclonus
reduction. Right GPi therapeutic amplitudes ranged from 2.5 to 3.4 V
and PW 60–140 ms, whereas left GPi therapeutic amplitudes ranged
from 3.1 to 3.4 V and PW 60–90 ms.
Patient 2 developed left shoulder rolling movements during the
course of the programming that were consistent with tics, because they
were stereotyped, suppressible, and associated with a premonitory
urge. This tic responded to a longer PW. Patient 1 is no longer on
medications for his myoclonus, and Patient 2 is being tapered off oral
medications and has not required further botulinum toxin injections.
Discussion
DBS of the GPi and ventral intermediate nucleus (VIM) of the
thalamus has emerged as a promising therapy for the treatment of
refractory MD. Both patients developed isolated myoclonus that was
Video 1. Pre- and Postoperative Examinations for Patient 1. In the pre-surgical state, the patient has persistent truncal and left arm myoclonus while
sitting, during rest, and walking. Three years with bilateral globus pallidus internus deep brain stimulation there is no visible myoclonus.
Video 2. Pre- and Postoperative Examinations for Patient 2. In the pre-surgical state, the patient has myoclonic jerks of the right arm at rest and when
writing. Right leg myoclonus emerges when she walks. At 1 and 3 months with bilateral globus pallidus internus deep brain stimulation, there is no rest or action
myoclonus.
Ramdhani RA, Frucht SJ, Behnegar A, et al. DBS for Isolated Myoclonus in Myoclonus Dystonia
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DBS for Isolated Myoclonus in Myoclonus Dystonia Ramdhani RA, Frucht SJ, Behnegar A, et al.
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services5
refractory to medical therapy. A robust myoclonus response was
appreciated as early as 1 week from initiation of stimulation.
Furthermore, there was less variability in the time to significant motor
response in our patients than DBS in primary generalized dystonia.20
The dramatic results seen in Patient 1 are consistent with previously
published data in SGCE-positive patients. Table 2 provides a summary
of case reports and series of SGCE-positive patients treated with GPi-
DBS. Myoclonus improvement ranged from 61% to 93% across the
studies, with the majority of patients reported as having concomitant
dystonia. Long-term sustained benefits from GPi-DBS were even
reported at 10 years. SGCE-negative patients demonstrated less benefit
(Table 3) with GPi-DBS, with myoclonus reduction ranging from 30%
to 60%. Our SGCE-negative patient achieved substantial amelioration
of all aspects of her myoclonus; however, the small number of reported
SGCE-negative cases treated with DBS limits any speculation to a
possible differential response to stimulation between SGCE-positive
and SGCE-negative patients.
MD tends to produce myoclonic jerks and dystonia in the upper
body. The lower limb predominant action myoclonus of Patient 2 is
not only unique, but reveals the phenotypic variability of this rare
condition.4 Furthermore, while a variable proportion (21–80%) of
patients with MD have the SGCE mutation, recent identification of
mutations in the RELN gene in a subset of SGCE-negative patients,
reflects the genetic heterogeneity of this condition.21 Among the
familial cohort found to have the RELN mutation, one patient was
reported to have lower limb myoclonus.
Benefits across the published studies (Tables 2 and 3) were attained
with high-frequency stimulation (range 120–185 Hz) and median
amplitudes of 2.34–3.2 V for SGCE-negative and SGCE-positive
patients, respectively. Although the mechanism underlying myoclonus
remains unknown, neurophysiological data reveal that GPi neurons
have a higher burst frequency with shorter pauses in MD than primary
generalized dystonia.22 Pallidal local field potential recordings from MD
patients also demonstrate oscillatory activity in the 3–15 Hz frequency
band that synchronize with muscle activity.23 Based on the growing
evidence that striatopallidal network changes play a role in MD, we can
hypothesize that a possible mechanism for the benefits achieved with
GPi-DBS may be rooted in the regularization and desynchronization of
abnormal neuronal activity and oscillations, paralleling similar
suggested mechanisms of action in Parkinson’s disease24 and dystonia.25
In addition to striatopallidal dysfunction, cerebellar–thalamic network
aberrancy26,27 via the parasagittal cerebellum, pontine nuclei, and posterior
thalamus has also been implicated in SGCE-positive MD patients.28,29 The
therapeutic benefit of thalamic DBS in treating myoclonus in MD
patients10 might therefore be related to changes in this network. However,
stimulation is usually in the ventral tier of the nucleus, and because of the
overlap and lack of clarity of efferent fiber differentiation, it remains
uncertain which network is being influenced with stimulation.
In summary, we present two cases of isolated myoclonus in MD, one
SGCE positive and the other SGCE negative, both of which were
effectively treated with bilateral pallidal stimulation. High-frequency
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myoclonus. Benefits were realized within 1 month of initial program-
ming and continue to be sustained in both patients.
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